Warm congratulations on the successful holding of the 10th China ....

release time:2022-09-19 16:48:01

The 10th China Cervical Cancer Prevention and Treatment Engineering Annual Conference and the sixth National Cervical Intraepithelial Neoplasia and Cervical Cancer Diagnosis and Treatment Hot Issues Summit Forum was held in Taiyuan, Shanxi Province on September 15-18, 2022. Professor Cao Zeyi, Director of China Cervical Cancer Prevention Project, Professor Hao Min from the Second Hospital of Shanxi Medical University, Professor Sui Long from Obstetrics and Gynecology Hospital of Fudan University and many other senior experts and scholars in the field attended the forum.
At the meeting, Professor Hao Min shared a wonderful lecture on "The clinical significance of fusion factor in the treatment of HPV infection for the prevention and treatment of cervical cancer". Professor Hao shared four aspects of clinical trial research, clinical treatment status, new clinical treatment methods - "fusion factor" and "fusion factor" clinical trials. Professor Hao highly evaluated the fusion factor, a new clinical treatment method, and elaborated the antiviral principle and characteristics of the fusion factor. He pointed out that the fusion factor has the characteristics of physical adsorption of HPV virus particles, penetration of cell membrane structure, regulation of immune response, blocking HPV infection pathway, clearing latent virus to reduce autologous transmission and so on.

Professor Hao said that "Fusion factor" has carried out a large number of clinical trials, including "cell experiments by the Institute of Virology and other scientific research institutions of the Chinese Academy of Sciences confirmed that fusion factor can effectively block viral infection and activate immune cells" and "clinical observation by Hongfu Hospital of Fudan University confirmed that fusion factor gel products can effectively reduce hpv load, inhibit recurrence, and recommend clinical application". Its effectiveness and safety have been fully proved. Professor Hao gave full affirmation to our company's "PHPV fusion factor vaginal antibacterial gel" product, and expected our company's product to make greater contribution to the clinical research and practice of HPV treatment.

Professor Hao Min explains our products

Chairman Cao Zeyi and Professor Hao Min visited the booth to guide the work

Take Photos with Experts